The 340B program is a United States federal government program created in 1992. It requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. These entities include hospitals serving a disproportionate share of low-income patients, federally qualified health centers, and other specific types of healthcare providers. The intent of the program is to allow these organizations to stretch scarce federal resources, enabling them to serve more eligible patients and provide more comprehensive services.
Understanding a previous administration’s stance toward policies affecting the 340B program requires examining actions taken during its tenure. Any alterations to program rules, implementation, or funding mechanisms enacted by the administration, as well as statements made by leading figures, offer insights into their overall view. The impact of such actions can then be evaluated regarding its effects on participating healthcare providers and their ability to deliver care to vulnerable populations. Historically, adjustments to the 340B program have triggered debate regarding access to affordable medications and the financial sustainability of healthcare providers serving underserved communities.
